{"entity":{"type":"insider","cik":"0001289946","url":"/insider/0001289946","json_url":"/insider/0001289946.json","name":"Broom Colin MD","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":41,"n_filings":18,"first":"2008-09-16","last":"2022-08-04","span_basis":"filed_date"},"name_variants":[{"name":"Broom Colin MD","source":"filing","n_filings":18,"first_seen":"2008-09-16","last_seen":"2022-08-04"}],"transactions":[{"id":6883432,"accession":"0001104659-22-086280","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-22-086280","line_url":"/filing/0001104659-22-086280#line-1","is_derivative":false,"issuer_cik":"0001289946","issuer_name":"Nabriva Therapeutics plc","issuer_ticker":"NBRV","issuer_name_source":null,"issuer_url":"/issuer/0001289946","owner_cik":"0001289946","owner_name":"Broom Colin MD","owner_display_name":"Broom Colin MD","owner_url":"/insider/0001289946","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5339.0,"shares_display":"5,339","price_per_share":0.1902,"price_display":"0.19","price_state":"stated","total_value":1015.4778,"total_display":"1,015.48","total_whole":"1,015","shares_owned_after":36523.0,"shares_owned_after_display":"36,523","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-08-02","filed_date":"2022-08-04","scope":"insider"},{"id":4514751,"accession":"0001104659-21-100289","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-21-100289","line_url":"/filing/0001104659-21-100289#line-1","is_derivative":false,"issuer_cik":"0001289946","issuer_name":"Nabriva Therapeutics plc","issuer_ticker":"NBRV","issuer_name_source":null,"issuer_url":"/issuer/0001289946","owner_cik":"0001289946","owner_name":"Broom Colin MD","owner_display_name":"Broom Colin MD","owner_url":"/insider/0001289946","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":531.0,"shares_display":"531","price_per_share":1.2,"price_display":"1.20","price_state":"stated","total_value":637.2,"total_display":"637.20","total_whole":"637","shares_owned_after":41862.0,"shares_owned_after_display":"41,862","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-08-02","filed_date":"2021-08-04","scope":"insider"},{"id":3287848,"accession":"0001104659-20-097717","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-20-097717","line_url":"/filing/0001104659-20-097717#line-2","is_derivative":false,"issuer_cik":"0001289946","issuer_name":"Nabriva Therapeutics plc","issuer_ticker":"NBRV","issuer_name_source":null,"issuer_url":"/issuer/0001289946","owner_cik":"0001289946","owner_name":"Broom Colin MD","owner_display_name":"Broom Colin MD","owner_url":"/insider/0001289946","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11064.0,"shares_display":"11,064","price_per_share":0.6476,"price_display":"0.65","price_state":"stated","total_value":7165.0464,"total_display":"7,165.05","total_whole":"7,165","shares_owned_after":248936.0,"shares_owned_after_display":"248,936","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-08-20","filed_date":"2020-08-21","scope":"insider"},{"id":8310285,"accession":"0001104659-19-048436","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-19-048436","line_url":"/filing/0001104659-19-048436#line-1","is_derivative":false,"issuer_cik":"0001289946","issuer_name":"Nabriva Therapeutics plc","issuer_ticker":"NBRV","issuer_name_source":null,"issuer_url":"/issuer/0001289946","owner_cik":"0001289946","owner_name":"Broom Colin MD","owner_display_name":"Broom Colin MD","owner_url":"/insider/0001289946","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10177.0,"shares_display":"10,177","price_per_share":2.0309,"price_display":"2.03","price_state":"stated","total_value":20668.4693,"total_display":"20,668.47","total_whole":"20,668","shares_owned_after":208750.0,"shares_owned_after_display":"208,750","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-08-30","filed_date":"2019-09-03","scope":"insider"},{"id":9223465,"accession":"0001104659-19-047351","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-19-047351","line_url":"/filing/0001104659-19-047351#line-1","is_derivative":false,"issuer_cik":"0001289946","issuer_name":"Nabriva Therapeutics plc","issuer_ticker":"NBRV","issuer_name_source":null,"issuer_url":"/issuer/0001289946","owner_cik":"0001289946","owner_name":"Broom Colin MD","owner_display_name":"Broom Colin MD","owner_url":"/insider/0001289946","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10177.0,"shares_display":"10,177","price_per_share":2.07,"price_display":"2.07","price_state":"stated","total_value":21066.39,"total_display":"21,066.39","total_whole":"21,066","shares_owned_after":125724.0,"shares_owned_after_display":"125,724","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-08-21","filed_date":"2019-08-26","scope":"insider"},{"id":6352578,"accession":"0001104659-18-041953","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-18-041953","line_url":"/filing/0001104659-18-041953#line-1","is_derivative":false,"issuer_cik":"0001289946","issuer_name":"Nabriva Therapeutics plc","issuer_ticker":"NBRV","issuer_name_source":null,"issuer_url":"/issuer/0001289946","owner_cik":"0001289946","owner_name":"Broom Colin MD","owner_display_name":"Broom Colin MD","owner_url":"/insider/0001289946","role":"Director, Officer (CEO & Director)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO & Director","security_title":"Ordinary Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":3.72,"price_display":"3.72","price_state":"stated","total_value":18600.0,"total_display":"18,600.00","total_whole":"18,600","shares_owned_after":102151.0,"shares_owned_after_display":"102,151","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-06-22","filed_date":"2018-06-25","scope":"insider"},{"id":6540836,"accession":"0001104659-18-035535","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-18-035535","line_url":"/filing/0001104659-18-035535#line-1","is_derivative":false,"issuer_cik":"0001289946","issuer_name":"Nabriva Therapeutics plc","issuer_ticker":"NBRV","issuer_name_source":null,"issuer_url":"/issuer/0001289946","owner_cik":"0001289946","owner_name":"Broom Colin MD","owner_display_name":"Broom Colin MD","owner_url":"/insider/0001289946","role":"Director, Officer (CEO & Director)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO & Director","security_title":"Ordinary Shares F1","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":4.6,"price_display":"4.60","price_state":"stated","total_value":46000.0,"total_display":"46,000.00","total_whole":"46,000","shares_owned_after":97151.0,"shares_owned_after_display":"97,151","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-05-23","filed_date":"2018-05-23","scope":"insider"},{"id":5350047,"accession":"0001104659-17-058896","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-17-058896","line_url":"/filing/0001104659-17-058896#line-1","is_derivative":false,"issuer_cik":"0001289946","issuer_name":"Nabriva Therapeutics plc","issuer_ticker":"NBRV","issuer_name_source":null,"issuer_url":"/issuer/0001289946","owner_cik":"0001289946","owner_name":"Broom Colin MD","owner_display_name":"Broom Colin MD","owner_url":"/insider/0001289946","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Ordinary Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2588.0,"shares_display":"2,588","price_per_share":8.35,"price_display":"8.35","price_state":"stated","total_value":21609.8,"total_display":"21,609.80","total_whole":"21,610","shares_owned_after":87151.0,"shares_owned_after_display":"87,151","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-22","filed_date":"2017-09-26","scope":"insider"},{"id":4477463,"accession":"0001474064-13-000022","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001474064-13-000022","line_url":"/filing/0001474064-13-000022#line-2","is_derivative":false,"issuer_cik":"0000890465","issuer_name":"NPS PHARMACEUTICALS INC","issuer_ticker":"NPSP","issuer_name_source":null,"issuer_url":"/issuer/0000890465","owner_cik":"0001289946","owner_name":"Broom Colin MD","owner_display_name":"Broom Colin MD","owner_url":"/insider/0001289946","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6100.0,"shares_display":"6,100","price_per_share":8.74,"price_display":"8.74","price_state":"stated","total_value":53314.0,"total_display":"53,314.00","total_whole":"53,314","shares_owned_after":9125.0,"shares_owned_after_display":"9,125","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-02-07","filed_date":"2013-02-11","scope":"insider"},{"id":9227194,"accession":"0001127602-12-035162","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-12-035162","line_url":"/filing/0001127602-12-035162#line-1","is_derivative":false,"issuer_cik":"0001289946","issuer_name":"VIROPHARMA INC","issuer_ticker":"VPHM","issuer_name_source":null,"issuer_url":"/issuer/0001289946","owner_cik":"0001289946","owner_name":"Broom Colin MD","owner_display_name":"Broom Colin MD","owner_url":"/insider/0001289946","role":"Officer (VP & Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (VP & Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP & Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":17500.0,"shares_display":"17,500","price_per_share":22.5315,"price_display":"22.53","price_state":"stated","total_value":394301.25,"total_display":"394,301.25","total_whole":"394,301","shares_owned_after":20167.0,"shares_owned_after_display":"20,167","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-12-24","filed_date":"2012-12-28","scope":"insider"},{"id":2487866,"accession":"0001127602-12-035085","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001127602-12-035085","line_url":"/filing/0001127602-12-035085#line-2","is_derivative":false,"issuer_cik":"0000946840","issuer_name":"VIROPHARMA INC","issuer_ticker":"VPHM","issuer_name_source":null,"issuer_url":"/issuer/0000946840","owner_cik":"0001289946","owner_name":"Broom Colin MD","owner_display_name":"Broom Colin MD","owner_url":"/insider/0001289946","role":"Officer (VP & Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (VP & Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP & Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":17500.0,"shares_display":"17,500","price_per_share":22.5315,"price_display":"22.53","price_state":"stated","total_value":394301.25,"total_display":"394,301.25","total_whole":"394,301","shares_owned_after":37667.0,"shares_owned_after_display":"37,667","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-12-24","filed_date":"2012-12-27","scope":"insider"},{"id":3065105,"accession":"0001127602-12-033702","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001127602-12-033702","line_url":"/filing/0001127602-12-033702","is_derivative":false,"issuer_cik":"0000946840","issuer_name":"VIROPHARMA INC","issuer_ticker":"VPHM","issuer_name_source":null,"issuer_url":"/issuer/0000946840","owner_cik":"0001289946","owner_name":"Broom Colin MD","owner_display_name":"Broom Colin MD","owner_url":"/insider/0001289946","role":"Officer (VP & Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (VP & Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP & Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":74999.0,"shares_display":"74,999","price_per_share":24.0672,"price_display":"24.07","price_state":"stated","total_value":1805015.9328,"total_display":"1,805,015.93","total_whole":"1,805,016","shares_owned_after":37667.0,"shares_owned_after_display":"37,667","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-12-10","filed_date":"2012-12-12","scope":"insider","n_lines":3},{"id":9089816,"accession":"0001127602-11-032359","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001127602-11-032359","line_url":"/filing/0001127602-11-032359","is_derivative":false,"issuer_cik":"0000946840","issuer_name":"VIROPHARMA INC","issuer_ticker":"VPHM","issuer_name_source":null,"issuer_url":"/issuer/0000946840","owner_cik":"0001289946","owner_name":"Broom Colin MD","owner_display_name":"Broom Colin MD","owner_url":"/insider/0001289946","role":"Officer (VP & Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (VP & Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP & Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50000.0,"shares_display":"50,000","price_per_share":25.335,"price_display":"25.34","price_state":"stated","total_value":1266750.0,"total_display":"1,266,750.00","total_whole":"1,266,750","shares_owned_after":19439.0,"shares_owned_after_display":"19,439","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-12-14","filed_date":"2011-12-15","scope":"insider","n_lines":2},{"id":9012452,"accession":"0001127602-11-032247","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001127602-11-032247","line_url":"/filing/0001127602-11-032247#line-4","is_derivative":false,"issuer_cik":"0000946840","issuer_name":"VIROPHARMA INC","issuer_ticker":"VPHM","issuer_name_source":null,"issuer_url":"/issuer/0000946840","owner_cik":"0001289946","owner_name":"Broom Colin MD","owner_display_name":"Broom Colin MD","owner_url":"/insider/0001289946","role":"Officer (VP & Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (VP & Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP & Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22330.0,"shares_display":"22,330","price_per_share":23.5,"price_display":"23.50","price_state":"stated","total_value":524755.0,"total_display":"524,755.00","total_whole":"524,755","shares_owned_after":19439.0,"shares_owned_after_display":"19,439","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-12-13","filed_date":"2011-12-14","scope":"insider"},{"id":9012450,"accession":"0001127602-11-032247","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001127602-11-032247","line_url":"/filing/0001127602-11-032247#line-2","is_derivative":false,"issuer_cik":"0000946840","issuer_name":"VIROPHARMA INC","issuer_ticker":"VPHM","issuer_name_source":null,"issuer_url":"/issuer/0000946840","owner_cik":"0001289946","owner_name":"Broom Colin MD","owner_display_name":"Broom Colin MD","owner_url":"/insider/0001289946","role":"Officer (VP & Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (VP & Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP & Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":17670.0,"shares_display":"17,670","price_per_share":23.5041,"price_display":"23.50","price_state":"stated","total_value":415317.447,"total_display":"415,317.45","total_whole":"415,317","shares_owned_after":19439.0,"shares_owned_after_display":"19,439","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-12-12","filed_date":"2011-12-14","scope":"insider"},{"id":9179800,"accession":"0001127602-11-028951","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001127602-11-028951","line_url":"/filing/0001127602-11-028951","is_derivative":false,"issuer_cik":"0000946840","issuer_name":"VIROPHARMA INC","issuer_ticker":"VPHM","issuer_name_source":null,"issuer_url":"/issuer/0000946840","owner_cik":"0001289946","owner_name":"Broom Colin MD","owner_display_name":"Broom Colin MD","owner_url":"/insider/0001289946","role":"Officer (VP & Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (VP & Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP & Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":21.0001,"price_display":"21.00","price_state":"stated","total_value":420002.0,"total_display":"420,002.00","total_whole":"420,002","shares_owned_after":19639.0,"shares_owned_after_display":"19,639","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-11-07","filed_date":"2011-11-08","scope":"insider","n_lines":2},{"id":8898449,"accession":"0001127602-11-028417","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001127602-11-028417","line_url":"/filing/0001127602-11-028417#line-4","is_derivative":false,"issuer_cik":"0000946840","issuer_name":"VIROPHARMA INC","issuer_ticker":"VPHM","issuer_name_source":null,"issuer_url":"/issuer/0000946840","owner_cik":"0001289946","owner_name":"Broom Colin MD","owner_display_name":"Broom Colin MD","owner_url":"/insider/0001289946","role":"Officer (VP & Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (VP & Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP & Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":24121.0,"shares_display":"24,121","price_per_share":20.0506,"price_display":"20.05","price_state":"stated","total_value":483640.5226,"total_display":"483,640.52","total_whole":"483,641","shares_owned_after":19439.0,"shares_owned_after_display":"19,439","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-11-01","filed_date":"2011-11-02","scope":"insider"},{"id":8898445,"accession":"0001127602-11-028417","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001127602-11-028417","line_url":"/filing/0001127602-11-028417#line-2","is_derivative":false,"issuer_cik":"0000946840","issuer_name":"VIROPHARMA INC","issuer_ticker":"VPHM","issuer_name_source":null,"issuer_url":"/issuer/0000946840","owner_cik":"0001289946","owner_name":"Broom Colin MD","owner_display_name":"Broom Colin MD","owner_url":"/insider/0001289946","role":"Officer (VP & Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (VP & Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP & Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20495.0,"shares_display":"20,495","price_per_share":20.4223,"price_display":"20.42","price_state":"stated","total_value":418555.0385,"total_display":"418,555.04","total_whole":"418,555","shares_owned_after":19439.0,"shares_owned_after_display":"19,439","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-10-31","filed_date":"2011-11-02","scope":"insider"},{"id":7562664,"accession":"0001127602-10-022961","txn_seq":20,"anchor":"line-20","filing_url":"/filing/0001127602-10-022961","line_url":"/filing/0001127602-10-022961","is_derivative":false,"issuer_cik":"0000946840","issuer_name":"VIROPHARMA INC","issuer_ticker":"VPHM","issuer_name_source":null,"issuer_url":"/issuer/0000946840","owner_cik":"0001289946","owner_name":"Broom Colin MD","owner_display_name":"Broom Colin MD","owner_url":"/insider/0001289946","role":"Officer (VP & Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (VP & Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP & Chief Scientific Officer","security_title":"Common Stock for Sales","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5060.0,"shares_display":"5,060","price_per_share":13.28205533596838,"price_display":"13.28","price_state":"stated","total_value":67207.2,"total_display":"67,207.20","total_whole":"67,207","shares_owned_after":18413.0,"shares_owned_after_display":"18,413","ownership_form":"D","is_10b5_1":null,"transaction_date":"2010-09-13","filed_date":"2010-09-13","scope":"insider","n_lines":7},{"id":7562645,"accession":"0001127602-10-022961","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0001127602-10-022961","line_url":"/filing/0001127602-10-022961","is_derivative":false,"issuer_cik":"0000946840","issuer_name":"VIROPHARMA INC","issuer_ticker":"VPHM","issuer_name_source":null,"issuer_url":"/issuer/0000946840","owner_cik":"0001289946","owner_name":"Broom Colin MD","owner_display_name":"Broom Colin MD","owner_url":"/insider/0001289946","role":"Officer (VP & Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (VP & Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP & Chief Scientific Officer","security_title":"Common Stock for Sales","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7900.0,"shares_display":"7,900","price_per_share":13.252088607594937,"price_display":"13.25","price_state":"stated","total_value":104691.5,"total_display":"104,691.50","total_whole":"104,692","shares_owned_after":15113.0,"shares_owned_after_display":"15,113","ownership_form":"D","is_10b5_1":null,"transaction_date":"2010-09-10","filed_date":"2010-09-13","scope":"insider","n_lines":5},{"id":7562635,"accession":"0001127602-10-022961","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001127602-10-022961","line_url":"/filing/0001127602-10-022961","is_derivative":false,"issuer_cik":"0000946840","issuer_name":"VIROPHARMA INC","issuer_ticker":"VPHM","issuer_name_source":null,"issuer_url":"/issuer/0000946840","owner_cik":"0001289946","owner_name":"Broom Colin MD","owner_display_name":"Broom Colin MD","owner_url":"/insider/0001289946","role":"Officer (VP & Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (VP & Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP & Chief Scientific Officer","security_title":"Common Stock for Sales","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":17040.0,"shares_display":"17,040","price_per_share":13.255099765258215,"price_display":"13.26","price_state":"stated","total_value":225866.9,"total_display":"225,866.90","total_whole":"225,867","shares_owned_after":15113.0,"shares_owned_after_display":"15,113","ownership_form":"D","is_10b5_1":null,"transaction_date":"2010-09-09","filed_date":"2010-09-13","scope":"insider","n_lines":5},{"id":3849131,"accession":"0001181431-08-053458","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001181431-08-053458","line_url":"/filing/0001181431-08-053458","is_derivative":false,"issuer_cik":"0000946840","issuer_name":"VIROPHARMA INC","issuer_ticker":"VPHM","issuer_name_source":null,"issuer_url":"/issuer/0000946840","owner_cik":"0001289946","owner_name":"Broom Colin MD","owner_display_name":"Broom Colin MD","owner_url":"/insider/0001289946","role":"Officer (VP & Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (VP & Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP & Chief Scientific Officer","security_title":"Common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25353.0,"shares_display":"25,353","price_per_share":14.249320790439,"price_display":"14.25","price_state":"stated","total_value":361263.03,"total_display":"361,263.03","total_whole":"361,263","shares_owned_after":22072.0,"shares_owned_after_display":"22,072","ownership_form":"D","is_10b5_1":null,"transaction_date":"2008-09-12","filed_date":"2008-09-16","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":41,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":4,"open_market":true},{"code":"S","label":"Open-market sale","n":37,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":41},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001641640","name":"Nabriva Therapeutics plc","url":"/issuer/0001641640","role":"Director, Officer (CEO & Director)","n_filings":8,"first_seen":"2017-09-26","last_seen":"2022-08-04"},{"type":"issuer","type_label":"ISSUER","cik":"0000890465","name":"NPS PHARMACEUTICALS INC","url":"/issuer/0000890465","role":"Director","n_filings":1,"first_seen":"2013-02-11","last_seen":"2013-02-11"},{"type":"issuer","type_label":"ISSUER","cik":"0000946840","name":"VIROPHARMA INC","url":"/issuer/0000946840","role":"Officer (VP & Chief Scientific Officer)","n_filings":9,"first_seen":"2008-09-16","last_seen":"2012-12-28"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001289946","retrieved_at":"2026-08-26T01:40:47+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}